Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program

NCT06253637 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

31

Enrollment

OTHER

Sponsor class

Conditions

T-Lymphocytic Leukemia, Acute

Interventions

DRUG: Daratumumab plus chemotherapy according to the national treatment program

Sponsor

Gruppo Italiano Malattie EMatologiche dell'Adulto